<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94934">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868997</url>
  </required_header>
  <id_info>
    <org_study_id>TED01RV</org_study_id>
    <secondary_id>FD004792-01A1</secondary_id>
    <nct_id>NCT01868997</nct_id>
  </id_info>
  <brief_title>Teprotumumab Treatment in Patients With Active Thyroid Eye Disease</brief_title>
  <official_title>A Multicenter, Double-masked, Placebo-controlled, Efficacy and Safety Study of an Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), in Patients With Active Thyroid Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>River Vision Development Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>River Vision Development Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and effectiveness of a
      fully human antibody compared to placebo in the treatment of patients with active thyroid
      eye disease.

      &quot;Funding Source - FDA OOPD&quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, double-masked, placebo-controlled, efficacy and safety study of RV 001, an
      insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human),
      administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from
      active thyroid eye disease (TED)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Analysis - Patients are considered responders if their Week 24 Clinical Activity Score decreases ≥ 2 points AND Proptosis decreases of ≥ 2 mm.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GO-Quality of Life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proptosis as a continuous variable</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Activity Score as a continuous variable</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Thyroid Associated Ophthalmopathies</condition>
  <condition>Thyroid-Associated Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>Saline or teprotumumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as an infusion every 3 weeks for 8 total over 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teprotumumab or saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg/kg first infusion then 20mg/kg for remaining 7 infusions administered every 3 weeks over 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teprotumumab</intervention_name>
    <description>10mg/kg first infusion then 20mg/kg for remaining 7 infusions administered every 3 weeks over 6 months</description>
    <arm_group_label>teprotumumab or saline</arm_group_label>
    <other_name>RV 001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution</description>
    <arm_group_label>Saline or teprotumumab</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Graves'disease associated with active thyroid eye disease and a
             clinical activity score of &gt;4

          -  Fewer than 9 months from onset of thyroid eye disease

          -  No previous medical or surgical treatment, excluding local supportive measures and
             steroids if the maximum cumulative dose is less than 1000 mg methylprednisolone or
             equivalent with at least 6 weeks between last administration of steroids and
             randomization

          -  Euthyroid or with mild hypo or hyperthyroidism defined as free thyroxine (FT4) and
             free triiodothyronine (FT3) levels less than 50% above or below the normal limits.
             Every effort should be made to correct the mild hypo or hyperthyroidism promptly.

        Exclusion Criteria:

          -  Optic neuropathy

          -  Corneal decompensation unresponsive to medical management

          -  Oral or IV steroid treatment for any reason in the preceding 3 months

          -  Poorly controlled diabetes

          -  Platelets &lt;100 x 109/L

          -  Hemoglobin concentration &gt; 2gr/dl below the lower limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond S Douglas, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Stein Eye Institute at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Department of Ophthalmology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics, Department of Ophthalmology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center at University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Department of Ophthalmology</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center Department of Ophthalmology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Eye Institute at University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Wellness Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, The Eye Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University Medical Center</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ca' Granda Ospedale Policlinico Graves GO Center</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pisa, Azienda Ospedaliera</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid Eye Disease, Graves Orbitopathy, Thyroid Associated</keyword>
  <keyword>Ophthalmopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
